Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An announcement from Luye Pharma Group ( (HK:2186) ) is now available.
Luye Pharma Group Ltd. announced its interim financial results for the first half of 2025, reporting a revenue increase of 3.5% to RMB3,181.1 million and a gross profit rise of 3.8% to RMB2,157.6 million. Despite these gains, the company experienced an 18.4% decline in net profit to RMB357.4 million and a 19.3% decrease in profit attributable to shareholders, reflecting increased selling, distribution, and finance costs. The company did not propose an interim dividend, indicating a cautious approach amidst these financial challenges.
The most recent analyst rating on (HK:2186) stock is a Buy with a HK$5.00 price target. To see the full list of analyst forecasts on Luye Pharma Group stock, see the HK:2186 Stock Forecast page.
More about Luye Pharma Group
Luye Pharma Group Ltd. is a pharmaceutical company incorporated in Bermuda, focusing on the development, production, and sale of innovative medications. The company operates in the healthcare industry, providing a range of pharmaceutical products aimed at improving patient outcomes.
Average Trading Volume: 114,262,377
Technical Sentiment Signal: Buy
Current Market Cap: HK$14.03B
Find detailed analytics on 2186 stock on TipRanks’ Stock Analysis page.